Kenvue (KVUE) is set to be acquired by personal care giant Kimberly-Clark in a deal worth $48.7 billion. This major development has led to a significant rise in Kenvue's share price, making it one of the most promising dividend stocks. However, despite majority approval from investors, some are expressing concerns about the deal due to Kenvue's ongoing Tylenol lawsuit in Texas. Asset management firms have been adjusting their shares in the company following this announcement, with some firms, including Deutsche Bank, updating their rating on the company. On the other hand, Versor Investments LP and Machina Capital S.A.S. have notably increased their stake in KVUE. Rivaling health companies may also show interest in Kenvue following the Kimberly-Clark announcement.
Kenvue KVUE News Analytics from Thu, 09 Oct 2025 07:00:00 GMT to Fri, 07 Nov 2025 12:34:56 GMT -
